JW (Cayman) Therapeutics Co (FRA:JNY) 1-Year Share Buyback Ratio : -0.80% (As of Dec. 2024 )

View and export this data going back to 2023. Start your Free Trial

What is JW (Cayman) Therapeutics Co 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. JW (Cayman) Therapeutics Co's current 1-Year Share Buyback Ratio was -0.80%.

FRA:JNY's 1-Year Share Buyback Ratio is ranked better than
81.35% of 1201 companies
in the Biotechnology industry
Industry Median: -13.7 vs FRA:JNY: -0.80

Competitive Comparison of JW (Cayman) Therapeutics Co's 1-Year Share Buyback Ratio

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co's 1-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

JW (Cayman) Therapeutics Co 1-Year Share Buyback Ratio Calculation

JW (Cayman) Therapeutics Co's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2023 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Dec. 2023 )
	=	(412.396	-	415.532)	/	412.396
	=	-0.8%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co (FRA:JNY) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

JW (Cayman) Therapeutics Co 1-Year Share Buyback Ratio Related Terms

JW (Cayman) Therapeutics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (FRA:JNY) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

02126:Hong Kong

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co Headlines

No Headlines